Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)

C. Le Péchoux, A. Laplanche, C. Faivre-Finn, T. Ciuleanu, R. Wanders, D. Lerouge, R. Keus, M. Hatton, G. M. Videtic, S. Senan, A. Wolfson, R. Jones, R. Arriagada, E. Quoix, A. Dunant

Research output: Contribution to journalArticle

110 Scopus citations

Abstract

Background: We recently published the results of the PCI99 randomised trial comparing the effect of a prophylactic cranial irradiation (PCI) at 25 or 36 Gy on the incidence of brain metastases (BM) in 720 patients with limited small-cell lung cancer (SCLC). As concerns about neurotoxicity were a major issue surrounding PCI, we report here midterm and long-term repeated evaluation of neurocognitive functions and quality of life (QoL). Patients and methods: At predetermined intervals, the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and brain module were used for self-reported patient data, whereas the EORTC-Radiation Therapy Oncology Group Late Effects Normal Tissue-Subjective, Objective, Management, Analytic scale was used for clinicians' assessment. For each scale, the unfavourable status was analysed with a logistic model including age, grade at baseline, time and PCI dose. Results: Over the 3 years studied, there was no significant difference between the two groups in any of the 17 selected items assessing QoL and neurological and cognitive functions. We observed in both groups a mild deterioration across time of communication deficit, weakness of legs, intellectual deficit and memory (all P < 0.005). Conclusion: Patients should be informed of these potential adverse effects, as well as the benefit of PCI on survival and BM. PCI with a total dose of 25 Gy remains the standard of care in limited-stage SCLC.

Original languageEnglish (US)
Pages (from-to)1154-1163
Number of pages10
JournalAnnals of Oncology
Volume22
Issue number5
DOIs
StatePublished - 2011

Keywords

  • Limited disease
  • Neurocognitive evaluation
  • Phase III clinical trial
  • Prophylactic cranial irradiation
  • Quality of life
  • Small-cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01)'. Together they form a unique fingerprint.

  • Cite this

    Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., Keus, R., Hatton, M., Videtic, G. M., Senan, S., Wolfson, A., Jones, R., Arriagada, R., Quoix, E., & Dunant, A. (2011). Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Annals of Oncology, 22(5), 1154-1163. https://doi.org/10.1093/annonc/mdq576